PDF file - 104K, Supplementary Table S1. Vismodegib Dosing Strategy Supplementary Table S2. Commonly Reported Adverse Events According to Grade Supplementary Table S3. Pharmacokinetics of Unbound Vismodegib in Pediatric Patients with Medulloblastoma

PDF file - 156K, Supplementary Fig. S1. Concentration-time plots of the first 72 hours after administration of the first vismodegib dose during Course 1 to the patients in the initial cohort: 6 received 85 mg/m2 (Figure A & B), and 7 received 170 mg/m2 (Figure C &D). Plasma concentrations of total vismodegib (A, C) and unbound vismodegib (B, D) were measured. Supplementary Fig S2. The relation between total vismodegib plasma concentrations and alpha-1-acid glycoprotein (AAGP) plasma concentrations in pediatric patients. The scatter plot includes all data from patients treated in this study. The solid line represents the best-fit line from linear regression analysis (R2= 0.38).